Apex AI has a three-stage international expansion plan focusing on Korea, the U.S., and Japan, followed by a broader global rollout.
KFDA regulatory approval, and commercialization of AI-powered software for stomach and colorectal cancer diagnostics. KFDA application submitted by EOY 2025.
Direct sales targeting major health screening centers and collaborative marketing with the iKooB platform network covering 1,000 hospitals.
Collaboration with Next Biomedical and iKooB for AI-driven digestive health solutions, targeting university hospitals and affiliated research hospitals.
FDA approval application planned for EOY 2026.
Strategic collaborations:
Harvard MGH: Onboarding two Harvard-affiliated professors as advisors to facilitate expansion into major U.S. medical institutions.
Oracle Healthcare: Establishing strategic partnerships for AI integration.
Leveraging local investment networks to enhance market presence and sustainability.
Licensing AI technology to leading Japanese endoscopy manufacturers, including Olympus, Pentax, and Fujifilm.
Strategic collaboration with CEC, a Fujitsu subsidiary, to commercialize solutions within the Japanese healthcare market, including hospitals and screening centers.
Following successful market establishment in Korea, the U.S., and Japan, Apex AI aims to scale into Europe, China, and other high-demand international markets.
Expansion powered by cloud-based AI diagnostic solutions, establishing Apex AI as a global leader in AI-powered gastrointestinal cancer detection.
Last updated